Hajime Senjo

Kushiro, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications

Efgartigimod as a Steroid-sparing Therapy for Evans Syndrome: A Case Report.

Efgartigimod as a Steroid-sparing Therapy for Evans Syndrome: A Case Report.

Journal: Internal medicine (Tokyo, Japan)
Published: June 10, 2026

Characteristics of progressive multifocal leukoencephalopathy in hematological malignancies, With reference to HIV-infected patients.

Characteristics of progressive multifocal leukoencephalopathy in hematological malignancies, With reference to HIV-infected patients.

Journal: International journal of hematology
Published: April 01, 2026

Early administration of calcineurin inhibitors limits tolerogenic effect of PTCy in allogeneic hematopoietic transplant.

Early administration of calcineurin inhibitors limits tolerogenic effect of PTCy in allogeneic hematopoietic transplant.

Journal: Blood
Published: July 24, 2025

Donor T cell exhaustion and immune tolerance after allogeneic hematopoietic cell transplantation

Donor T cell exhaustion and immune tolerance after allogeneic hematopoietic cell transplantation

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: June 04, 2025

Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine-venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net.

Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine-venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net.

Journal: Blood cancer journal
Published: May 12, 2025

Intravenous Administration of Mesenchymal Stem Cell-Derived Exosome Alleviates Spinal Cord Injury by Regulating Neutrophil Extracellular Trap Formation through Exosomal miR-125a-3p.

Intravenous Administration of Mesenchymal Stem Cell-Derived Exosome Alleviates Spinal Cord Injury by Regulating Neutrophil Extracellular Trap Formation through Exosomal miR-125a-3p.

Journal: International journal of molecular sciences
Published: January 21, 2024

Event-free survival at 36 months is a suitable endpoint for diffuse large B-cell lymphoma patients treated with immunochemotherapy: real-world evidence from the North Japan Hematology Study Group.

Event-free survival at 36 months is a suitable endpoint for diffuse large B-cell lymphoma patients treated with immunochemotherapy: real-world evidence from the North Japan Hematology Study Group.

Journal: Haematologica
Published: December 09, 2023

Efficacy and Safety of Single-dose Pegfilgrastim for CD34 + Cell Mobilization in Healthy Volunteers: A Phase 2 Study.

Efficacy and Safety of Single-dose Pegfilgrastim for CD34 + Cell Mobilization in Healthy Volunteers: A Phase 2 Study.

Journal: Transplantation
Published: November 28, 2023

GVHD targets organoid-forming bile duct stem cells in a TGF-β-dependent manner.

GVHD targets organoid-forming bile duct stem cells in a TGF-β-dependent manner.

Journal: Blood
Published: October 27, 2023

Booster effect of a third mRNA-based COVID-19 vaccine dose in patients with myeloid malignancies.

Booster effect of a third mRNA-based COVID-19 vaccine dose in patients with myeloid malignancies.

Journal: Cancer medicine
Published: March 01, 2023

Calcineurin inhibitor inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT.

Calcineurin inhibitor inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT.

Journal: Blood
Published: January 26, 2023

Humoral response to mRNA-based COVID-19 vaccine and booster effect of a third dose in patients with mature T cell and NK-cell neoplasms.

Humoral response to mRNA-based COVID-19 vaccine and booster effect of a third dose in patients with mature T cell and NK-cell neoplasms.

Journal: Annals of hematology
Published: January 04, 2023
Showing 1-12 of 30

Last Updated: 09/26/2026